Myasthenia Gravis Market Size

Myasthenia Gravis Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The Myasthenia Gravis Market is expected to grow significantly. The current market size of $ 2.11 billion in 2024 is projected to reach $ 4.5 billion by 2035. This translates into a CAGR of 7.11% from 2025 to 2035, indicating a significant rise in the upcoming years. This growth is mainly due to the increasing prevalence of myasthenia gravis and the advancements in treatment. Awareness of the disease is increasing, and as diagnostics become more sophisticated, more patients are being identified and treated, which will lead to the growth of the market. There are several factors that are driving the growth of this market, such as the development of new drugs and biologicals that target the underlying mechanism of myasthenia gravis. There are also many players in this market, such as Alexion and Grifols, who are constantly investing in research and development to find new treatment options. Strategic alliances and collaborations to enhance the efficacy and effectiveness of drugs and patient outcomes are also expected to drive the market. Recent product launches and clinical trials focusing on monoclonal antibodies and immunotherapy are expected to further drive the market and address unmet medical needs and improve the quality of life of patients.

Regional Market Size

Regional Deep Dive

The Myasthenia Gravis market is characterized by an increase in the awareness of the disease and the introduction of new treatment options across regions. The market in North America is driven by a well-established health care system, substantial R&D expenditure, and a high prevalence of autoimmune diseases. The Europe region is characterized by a diverse regulatory landscape and treatment access. Asia-Pacific is characterized by a high prevalence of autoimmune diseases and increasing health care spending, which are expected to drive the market growth. Middle East and Africa is characterized by a lack of health care resources, but the interest in improving patient care is increasing. Latin America is characterized by steady growth, driven by increasing access to health care and an increased awareness of the disease.

North America

• A new therapy for myasthenia gravis, based on a new type of drug, has recently been approved by the Food and Drug Administration of the United States. This new treatment, based on complement inhibition, will improve the choice of treatments available to patients.
• The Myasthenia Gravis Foundation of America (MGFA) is an organization which has the task of increasing public knowledge and of supporting research, which is essential to the improvement of treatment and support for the patient.
• The increasing frequency of autoimmune diseases in the United States has led to an increased emphasis on early diagnosis and individualized treatment, thereby increasing the market.

Europe

• The European Medicines Agency has accelerated the approval of new medicines, which encourages the pharmaceutical industry to develop new treatments for myasthenia gravis.
• Germany and France, for example, are leading in clinical trials of new therapies. And the companies like Roche and Novartis, which are developing new drugs, are contributing greatly to the effort.
• Culture has a great influence on the treatment and the involvement of the patient in Myasthenia Gravis.

Asia-Pacific

• Japan and Australia are now spending more on health, which has led to better access to treatments and diagnostic tools for Myasthenia gravis.
• In countries like India, the introduction of telemedicine has improved the availability of specialists, thereby facilitating early diagnosis and adherence to treatment.
• Local pharmaceutical companies are now collaborating more and more with international companies to develop affordable medicines for the local market.

MEA

• In the Region, the World Health Organization is working with governments to improve the health care system, which is needed for a better diagnosis and treatment of myasthenia gravis.
• NGO’s are increasingly interested in supporting awareness and education campaigns, especially in countries such as South Africa and Egypt.
• Culture and education are necessary to break down the barriers of the patient's reluctance to seek treatment for his chronic illness.

Latin America

• The increasing reorganization of the health service in Brazil and Mexico has led to an improvement in the availability of treatments and care for Myasthenia gravis.
• Local advocacy groups are now springing up to raise awareness of myasthenia gravis, which is vital for early diagnosis and treatment.
• Regulatory changes in Brazil are facilitating the approval of new drugs, which should help to increase the availability of these medicines in the market.

Did You Know?

“Myasthenia Gravis is an autoimmune disease affecting 1 in 100,000 people. It is a rare but important autoimmune disease, causing severe muscle weakness.” — Myasthenia Gravis Foundation of America (MGFA)

Segmental Market Size

Myasthenia gravis is a growing market, owing to increased awareness and the development of treatment options. There are two main reasons for this growth: the growing prevalence of the disease, which requires effective management, and the development of new treatments such as monoclonal antibodies and immunotherapy. The support from regulatory authorities for new treatments also encourages pharmaceutical companies to invest in research and development.

The current stage of the commercialisation of MG therapies is a mature one, with companies like Alexion and Grifols leading the way in the development of new therapies. The mainstays of therapy are immunosuppressants and cholinesterase inhibitors, which are vital in managing symptoms and improving patients’ quality of life. There are a number of trends in this market, such as the growing importance of personalised medicine and the growing use of telemedicine. Gene therapy and the development of new diagnostic tools are also influencing the future of MG therapy, with the promise of more effective and targeted treatments.

Future Outlook

From 2024 to 2035, the Myasthenia Gravis market is expected to grow at a CAGR of 7.11%, from $2.11 billion to $ 4.52 billion. The growth is due to the growing occurrence of the disease, the improvement of diagnostics and the development of new therapies. Moreover, the penetration of the market is expected to increase, reaching 15 to 20% of the patients with the disease by 2035, compared to about 10 to 15% in 2024.

Among the most important drivers of the industry is the development of new drugs based on biologicals and gene therapies, which offer more effective and individualized treatments. Also, the study of the pathophysiology of myasthenia gravis is expected to provide new therapeutic targets, which will further expand the therapeutic spectrum. In addition, the government's efforts to increase access to care and reimbursement for new therapies will play an important role in the growth of the market. Telemedicine and digital health solutions are expected to increase patient engagement and adherence to treatment regimens, which will also drive market growth. As the market evolves, it is essential for all market players to remain agile to seize opportunities and meet the needs of patients.